ERBB2 and breast cancer: On this basis, we conducted a multicenter, observational, retrospective study to primarily assess the tolerability of adjuvant T-DM1, with a secondary objective of evaluating its effectiveness in HER2+BC patients who had undergone NAT and had invasive residual disease at surgery.